Overview

A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LOXO-305) and Digoxin (P-Glycoprotein Substrate) in Healthy Participants

Status:
Completed

Trial end date:
2021-06-09

Target enrollment:

Participant gender:

Summary

The main purpose of this study is to evaluate the effect of Pirtobrutinib (LOXO-305) on multiple oral doses of digoxin (P-gp substrate) when administered as single and multiple doses by collecting the blood samples and conducting the blood tests to measure how much digoxin is in the bloodstream and how the body handles and eliminates it in healthy participants. The study will also evaluate the safety and tolerability of Pirtobrutinib. Participants will stay in this study for up to 58 days, including screening.

Phase:

Phase 1

Details

Lead Sponsor:

Eli Lilly and Company

Collaborator:

Loxo Oncology, Inc.

Treatments:

Digoxin
Pirtobrutinib